Full-Time

Surgical Technician

NAMSA

NAMSA

1,001-5,000 employees

Compensation Overview

$14.81 - $23/hr

Minneapolis, MN, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Bachelor’s degree in scientific discipline or Associate of Applied Science in Veterinary Technology required
  • 0-2 years related work experience
Responsibilities
  • Prepares surgical and cath lab suites for procedures, including setting up instruments and stocking study-specific supplies
  • Monitors anesthesia and animal vitals during surgical interventional procedures
  • Administers medications intra-procedure
  • Performs euthanasia
  • Collects laboratory samples, such as blood and urine, and processes them for analysis
  • Assists with specialized software-driven equipment, fluoroscopy and 3D imaging, etc. in support of procedures
  • Provides customer service to clients through professional interactions and by responding to client requests
  • Prepares and maintains surgical instruments through washing, drying and proper storage. Assembles surgical packs and processes sterile packs via autoclave or ethylene oxide
  • Operates, cleans and maintains gas anesthesia machines, autoclave and other surgical equipment routinely utilized
  • Maintains an efficient and clean work area by organizing and re-stocking cath labs, operating rooms, and the general storeroom as needed
  • Other duties as assigned
Desired Qualifications
  • Certified Veterinary Technician (CVT) or ALAT certification preferred
  • Knowledge of research animal physiology, pharmacology and general animal care preferred

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Toledo, Ohio

Founded

1967

Simplify Jobs

Simplify's Take

What believers are saying

  • Ophthalmic device market demands integrated solutions; partnership captures fragmented vendor consolidation opportunity.
  • Lexitas' 15-year ophthalmic track record and BCVA certification program strengthen trial execution quality.
  • Global reach across U.S., Europe, Asia-Pacific positions NAMSA for anterior/posterior segment cell/gene therapy trials.

What critics are saying

  • Integration failures from six acquisitions since 2021 disrupt operations and trigger client exodus.
  • Cultural misalignment between NAMSA's device focus and Lexitas' pharma-oriented model causes sponsor attrition.
  • FTC antitrust scrutiny targets NAMSA's biocompatibility dominance; divestitures dismantle end-to-end model.

What makes NAMSA unique

  • Unified ophthalmic platform embeds Lexitas' 700+ sites directly into NAMSA's device development infrastructure.
  • End-to-end lifecycle support from preclinical through commercialization under single contract and accountability.
  • Device-native expertise combines FDA endpoint fluency, IDE strategy, and ophthalmic clinical specialization.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at NAMSA who can refer or advise you

Benefits

Remote Work Options

Company News

PR Newswire
Mar 3rd, 2025
Namsa Completes Acquisition Of Wuxi Apptec Us Medical Device Testing Business

TOLEDO, Ohio, March 3, 2025 /PRNewswire/ -- NAMSA, a leading US based MedTech testing, clinical and regulatory consulting firm, announced that it finalized its acquisition of WuXi AppTec's US medical device testing operations on February 28.The acquisition brings together two of the most trusted names in medical device biological safety testing, serving more than 4,000 manufacturers worldwide.Lisa Olson, NAMSA Senior Vice President of Global Laboratory Services notes: "Together, we now have unmatched scientific expertise in biocompatibility, microbiology, preclinical and extractables and leachables testing. With the addition of WuXi AppTec medical device testing facilities in the US, we now have more scientists, more lab capacity and more expertise with a wider variety of medical devices than any other company. This combined expertise will continue to enable our work with clients to develop testing and consulting strategies tailored to their specific device and regulatory pathways."NAMSA has been expanding its reach in recent years as it continues to diversify its offering beyond biological safety testing. Since 2021, the company has acquired no fewer than six companies focused on preclinical or clinical research, making NAMSA one of the leading MedTech focused CROs. Brian Smith, NAMSA's recently appointed CEO noted: "This acquisition is part of our larger strategy to broaden our service offering and solidify our position as the go-to resource for manufacturers bringing new life-saving technologies to market while upholding the same high standards of client focused service you have come to expect from NAMSA."About NAMSAHelping medical device Sponsors improve healthcare since 1967, NAMSA is a leading global MedTech testing, clinical and regulatory consulting firm. With a deep pool of testing, clinical and regulatory experts, and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development

PR Newswire
Feb 24th, 2025
Brian P. Smith Joins Namsa As Chief Executive Officer; Brings 15+ Years Of Life Sciences Leadership Expertise To Role

TOLEDO, Ohio, Feb. 24, 2025 /PRNewswire/ -- NAMSA, a world-leading MedTech testing, clinical and regulatory consulting firm, announced today that Brian P. Smith has taken on the role of NAMSA's next Chief Executive Officer. Most recently, Brian served as the Chairman and Chief Executive Officer of Ad-Tech Medical Instrument Corp., a leading US neuro-diagnostic company.Andre-Michel Ballester, NAMSA's outgoing CEO, will transition back into his role as a managing partner of ARCHIMED, the healthcare-focused global private equity firm that holds a majority stake in NAMSA.Ballester led the search for a new CEO and notes: "Brian is globally recognized as a respected healthcare executive, having served in various leadership roles over the past 15 years as a Board Member, Operating Partner, Chairman of the Board, and Chief Executive Officer with extensive experience in operational, commercial, and innovation strategies. Brian's international experience, having lived and worked in Hong Kong, Shanghai, and Singapore, will be invaluable as we continue to expand our global footprint."Smith adds: "I am thrilled to join an organization with the history, reputation, and contribution to improved patient outcomes that NAMSA has repeatedly demonstrated for decades. I look forward to making my own contribution to this ongoing success story."NAMSA recently announced that it had signed a definitive agreement to purchase the US medical device testing operations of WuXi AppTec

BioSpace
Jan 17th, 2025
NAMSA Acquires the U.S. Medical Device Testing Operations of WuXi AppTec, Solidifying its Position as the Leader in MedTech Testing and Clinical Research

Under the agreement, NAMSA will acquire WuXi AppTec facilities in Minnesota and Georgia.

BioSpectrum Asia
Oct 16th, 2024
Japanese med tech leader Terumo announces strategic outsourcing partnership with Namsa

Japanese med tech leader Terumo announces strategic outsourcing partnership with Namsa.

Google
Jul 18th, 2023
NAMSA acquires german based CRI to expand clinical research and geographic reach across europe | business wire

NAMSA acquires german based CRI to expand clinical research and geographic reach across europe | business wire.